Source comparison
CJC-1295 No DAC vs DAC: Detailed Pharmacokinetics
Understanding the CJC-1295 no DAC vs DAC pharmacokinetic difference requires understanding the Drug Affinity Complex mechanism. CJC-1295 with DAC uses a reactive chemical group (maleimidopropionic acid) that forms a covalent bond with serum albumin’s Cys34 res
This comparison does not assign a generated winner or score.
- Understanding the CJC-1295 no DAC vs DAC pharmacokinetic difference requires understanding the Drug Affinity Complex mechanism. CJC-1295 with DAC uses a reactive chemical group (maleimidopropionic acid) that forms a covalent bond with serum albumin’s Cys34 residue after injection. This albumin binding protects the peptide from enzymatic degradation, extending its half-life from ~30 minutes to 6-8 days. The result: continuous GHRH receptor stimulation for nearly a week from a single injection.
- CJC-1295 no DAC (Mod GRF 1-29) lacks this albumin-binding modification. After injection, it circulates freely, activates pituitary GHRH receptors for approximately 30 minutes, and is then degraded by proteolytic enzymes. This brief activity window produces a discrete, defined GH pulse — then the stimulation stops, GH returns to baseline, and the somatotroph cells “reset” for the next stimulus. This reset is what preserves the pulsatile pattern that the CJC-1295 no DAC vs DAC comparison consistently favors.